MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 230 filers reported holding MYRIAD GENETICS INC in Q4 2019. The put-call ratio across all filers is 1.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $0 | – | 0 | – | 0.00% | – |
Q1 2021 | $0 | – | 0 | – | 0.00% | – |
Q4 2020 | $0 | – | 0 | – | 0.00% | – |
Q3 2020 | $0 | – | 0 | – | 0.00% | – |
Q2 2020 | $0 | – | 0 | – | 0.00% | – |
Q1 2020 | $0 | – | 0 | -100.0% | 0.00% | – |
Q4 2019 | $0 | – | 15 | – | 0.00% | – |
Q3 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
Q4 2018 | $6,000 | -93.8% | 225 | -89.3% | 0.00% | -100.0% |
Q3 2018 | $96,000 | +31.5% | 2,094 | +6.9% | 0.00% | +33.3% |
Q2 2018 | $73,000 | +73.8% | 1,959 | +58.8% | 0.00% | +50.0% |
Q1 2018 | $42,000 | 0.0% | 1,234 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $42,000 | +110.0% | 1,234 | +124.8% | 0.00% | +100.0% |
Q3 2017 | $20,000 | +300.0% | 549 | +175.9% | 0.00% | – |
Q2 2017 | $5,000 | 0.0% | 199 | -17.1% | 0.00% | – |
Q1 2017 | $5,000 | +25.0% | 240 | 0.0% | 0.00% | – |
Q4 2016 | $4,000 | -77.8% | 240 | -72.4% | 0.00% | -100.0% |
Q3 2016 | $18,000 | -33.3% | 870 | 0.0% | 0.00% | -50.0% |
Q2 2016 | $27,000 | -22.9% | 870 | +8.8% | 0.00% | 0.0% |
Q4 2015 | $35,000 | – | 800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |